The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Insulin Biologics and Biosimilars Market Research Report 2025
Synopsis
Insulin is a hormone created by your pancreas that controls the amount of glucose in your bloodstream at any given moment. It also helps store glucose in your liver, fat, and muscles. Finally, it regulates your body’s metabolism of carbohydrates, fats, and proteins.
Global Insulin Biologics and Biosimilars market is projected to reach US$ 36510 million in 2029, increasing from US$ 25780 million in 2022, with the CAGR of 5.1% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Insulin Biologics and Biosimilars market research.
The insulin biologics and biosimilars market is driven by the increasing prevalence of diabetes and the rising demand for effective and affordable insulin therapies. Insulin biologics play a critical role in managing diabetes and are widely used by patients worldwide. The growing diabetic population, along with the need for personalized and long-term insulin treatments, contributes to market growth. Additionally, advancements in biotechnology and insulin delivery systems have improved patient convenience and adherence. Biosimilars, which are highly similar versions of approved insulin biologics, offer cost-effective alternatives and have gained traction due to their potential to reduce healthcare expenditures and increase patient access. However, the market also faces challenges, including the complex regulatory pathway for biosimilars' approval, the need for extensive clinical comparability studies, and concerns regarding interchangeability and immunogenicity. Additionally, patent protection and market exclusivity of originator insulin products pose obstacles for biosimilar manufacturers. To succeed in this market, companies must navigate the regulatory landscape effectively, invest in research and development, demonstrate safety and efficacy of biosimilars, and collaborate with healthcare providers to promote the adoption of biosimilars and improve patient access to insulin therapies.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Insulin Biologics and Biosimilars market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novo Nordisk
Eli Lilly
Sanofi
Gan&Lee
Tonghua Dongbao
United Laboratory
Geropharm
Biocon
Wockhardt
Segment by Type
Insulin Biologics
Insulin Biosimilars
Segment by Application
Hospital
Retail Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Insulin Biologics and Biosimilars report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Insulin is a hormone created by your pancreas that controls the amount of glucose in your bloodstream at any given moment. It also helps store glucose in your liver, fat, and muscles. Finally, it regulates your body’s metabolism of carbohydrates, fats, and proteins.
Global Insulin Biologics and Biosimilars market is projected to reach US$ 36510 million in 2029, increasing from US$ 25780 million in 2022, with the CAGR of 5.1% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Insulin Biologics and Biosimilars market research.
The insulin biologics and biosimilars market is driven by the increasing prevalence of diabetes and the rising demand for effective and affordable insulin therapies. Insulin biologics play a critical role in managing diabetes and are widely used by patients worldwide. The growing diabetic population, along with the need for personalized and long-term insulin treatments, contributes to market growth. Additionally, advancements in biotechnology and insulin delivery systems have improved patient convenience and adherence. Biosimilars, which are highly similar versions of approved insulin biologics, offer cost-effective alternatives and have gained traction due to their potential to reduce healthcare expenditures and increase patient access. However, the market also faces challenges, including the complex regulatory pathway for biosimilars' approval, the need for extensive clinical comparability studies, and concerns regarding interchangeability and immunogenicity. Additionally, patent protection and market exclusivity of originator insulin products pose obstacles for biosimilar manufacturers. To succeed in this market, companies must navigate the regulatory landscape effectively, invest in research and development, demonstrate safety and efficacy of biosimilars, and collaborate with healthcare providers to promote the adoption of biosimilars and improve patient access to insulin therapies.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Insulin Biologics and Biosimilars market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novo Nordisk
Eli Lilly
Sanofi
Gan&Lee
Tonghua Dongbao
United Laboratory
Geropharm
Biocon
Wockhardt
Segment by Type
Insulin Biologics
Insulin Biosimilars
Segment by Application
Hospital
Retail Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Insulin Biologics and Biosimilars report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies' Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Insulin Biologics and Biosimilars Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Insulin Biologics
1.2.3 Insulin Biosimilars
1.3 Market by Application
1.3.1 Global Insulin Biologics and Biosimilars Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Insulin Biologics and Biosimilars Market Perspective (2018-2029)
2.2 Insulin Biologics and Biosimilars Growth Trends by Region
2.2.1 Global Insulin Biologics and Biosimilars Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Insulin Biologics and Biosimilars Historic Market Size by Region (2018-2023)
2.2.3 Insulin Biologics and Biosimilars Forecasted Market Size by Region (2024-2029)
2.3 Insulin Biologics and Biosimilars Market Dynamics
2.3.1 Insulin Biologics and Biosimilars Industry Trends
2.3.2 Insulin Biologics and Biosimilars Market Drivers
2.3.3 Insulin Biologics and Biosimilars Market Challenges
2.3.4 Insulin Biologics and Biosimilars Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Insulin Biologics and Biosimilars Players by Revenue
3.1.1 Global Top Insulin Biologics and Biosimilars Players by Revenue (2018-2023)
3.1.2 Global Insulin Biologics and Biosimilars Revenue Market Share by Players (2018-2023)
3.2 Global Insulin Biologics and Biosimilars Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Insulin Biologics and Biosimilars Revenue
3.4 Global Insulin Biologics and Biosimilars Market Concentration Ratio
3.4.1 Global Insulin Biologics and Biosimilars Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Insulin Biologics and Biosimilars Revenue in 2022
3.5 Insulin Biologics and Biosimilars Key Players Head office and Area Served
3.6 Key Players Insulin Biologics and Biosimilars Product Solution and Service
3.7 Date of Enter into Insulin Biologics and Biosimilars Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Insulin Biologics and Biosimilars Breakdown Data by Type
4.1 Global Insulin Biologics and Biosimilars Historic Market Size by Type (2018-2023)
4.2 Global Insulin Biologics and Biosimilars Forecasted Market Size by Type (2024-2029)
5 Insulin Biologics and Biosimilars Breakdown Data by Application
5.1 Global Insulin Biologics and Biosimilars Historic Market Size by Application (2018-2023)
5.2 Global Insulin Biologics and Biosimilars Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Insulin Biologics and Biosimilars Market Size (2018-2029)
6.2 North America Insulin Biologics and Biosimilars Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Insulin Biologics and Biosimilars Market Size by Country (2018-2023)
6.4 North America Insulin Biologics and Biosimilars Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Insulin Biologics and Biosimilars Market Size (2018-2029)
7.2 Europe Insulin Biologics and Biosimilars Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Insulin Biologics and Biosimilars Market Size by Country (2018-2023)
7.4 Europe Insulin Biologics and Biosimilars Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Insulin Biologics and Biosimilars Market Size (2018-2029)
8.2 Asia-Pacific Insulin Biologics and Biosimilars Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Insulin Biologics and Biosimilars Market Size by Region (2018-2023)
8.4 Asia-Pacific Insulin Biologics and Biosimilars Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Insulin Biologics and Biosimilars Market Size (2018-2029)
9.2 Latin America Insulin Biologics and Biosimilars Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Insulin Biologics and Biosimilars Market Size by Country (2018-2023)
9.4 Latin America Insulin Biologics and Biosimilars Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Insulin Biologics and Biosimilars Market Size (2018-2029)
10.2 Middle East & Africa Insulin Biologics and Biosimilars Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Insulin Biologics and Biosimilars Market Size by Country (2018-2023)
10.4 Middle East & Africa Insulin Biologics and Biosimilars Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novo Nordisk
11.1.1 Novo Nordisk Company Detail
11.1.2 Novo Nordisk Business Overview
11.1.3 Novo Nordisk Insulin Biologics and Biosimilars Introduction
11.1.4 Novo Nordisk Revenue in Insulin Biologics and Biosimilars Business (2018-2023)
11.1.5 Novo Nordisk Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Detail
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Insulin Biologics and Biosimilars Introduction
11.2.4 Eli Lilly Revenue in Insulin Biologics and Biosimilars Business (2018-2023)
11.2.5 Eli Lilly Recent Development
11.3 Sanofi
11.3.1 Sanofi Company Detail
11.3.2 Sanofi Business Overview
11.3.3 Sanofi Insulin Biologics and Biosimilars Introduction
11.3.4 Sanofi Revenue in Insulin Biologics and Biosimilars Business (2018-2023)
11.3.5 Sanofi Recent Development
11.4 Gan&Lee
11.4.1 Gan&Lee Company Detail
11.4.2 Gan&Lee Business Overview
11.4.3 Gan&Lee Insulin Biologics and Biosimilars Introduction
11.4.4 Gan&Lee Revenue in Insulin Biologics and Biosimilars Business (2018-2023)
11.4.5 Gan&Lee Recent Development
11.5 Tonghua Dongbao
11.5.1 Tonghua Dongbao Company Detail
11.5.2 Tonghua Dongbao Business Overview
11.5.3 Tonghua Dongbao Insulin Biologics and Biosimilars Introduction
11.5.4 Tonghua Dongbao Revenue in Insulin Biologics and Biosimilars Business (2018-2023)
11.5.5 Tonghua Dongbao Recent Development
11.6 United Laboratory
11.6.1 United Laboratory Company Detail
11.6.2 United Laboratory Business Overview
11.6.3 United Laboratory Insulin Biologics and Biosimilars Introduction
11.6.4 United Laboratory Revenue in Insulin Biologics and Biosimilars Business (2018-2023)
11.6.5 United Laboratory Recent Development
11.7 Geropharm
11.7.1 Geropharm Company Detail
11.7.2 Geropharm Business Overview
11.7.3 Geropharm Insulin Biologics and Biosimilars Introduction
11.7.4 Geropharm Revenue in Insulin Biologics and Biosimilars Business (2018-2023)
11.7.5 Geropharm Recent Development
11.8 Biocon
11.8.1 Biocon Company Detail
11.8.2 Biocon Business Overview
11.8.3 Biocon Insulin Biologics and Biosimilars Introduction
11.8.4 Biocon Revenue in Insulin Biologics and Biosimilars Business (2018-2023)
11.8.5 Biocon Recent Development
11.9 Wockhardt
11.9.1 Wockhardt Company Detail
11.9.2 Wockhardt Business Overview
11.9.3 Wockhardt Insulin Biologics and Biosimilars Introduction
11.9.4 Wockhardt Revenue in Insulin Biologics and Biosimilars Business (2018-2023)
11.9.5 Wockhardt Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
